Gilead Sciences’ Tubulis acquisition brings antibody drug conjugates in clinical development for cancer. Analysts say the Tubulis platform technologies that yielded these ADCs could also help Gilead develop drugs in other therapeutic areas.
The post Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis appeared first on MedCity News.
